Jeffpacman -
Thank you for all the upbeat messages on AEMD. I like your "cautious" optimism.
If one sees the research in the field of exosomes, it seems that there is tremendous potential. And it seems like now there is enough momentum, that it is going to continue. All the pieces slowly are falling together and while that is happening, looks like it is providing some answers, so far unknown, in the field of oncology.
My question, for a long time, has been what more applications does AEMD have for Oncology? We know a few vague things about exosomes. I have a very strong feeling that there is a lot going in the background at AEMD with respect to different fields of Cancer and what we know is only the tip of the iceberg.
Also, are there any thoughts for using the HP as a therapeutic agent? If the HP is successfully used in clinical trials for removing exosomes as a therapy (or as an adjuvant) even in one kind of cancer, then the sky will be the limit for AEMD. That will only open it up for other cancer therapies. The exosome field is already on a roll and I think we are lucky that it AEMD landed up as an exosome related company so early in the game. JJ needs a lot of credit for his foresight on this, associating with big players like M.D.Anderson and of course hiring Dr. Taylor.
However, over the next few years, the company may see more revenues from the DARPA sepsis program before revenues from exosomes. As we know there is no therapeutic agent for sepsis. DARPA took on this challenge and from the various PRs AEMD releases, it seems they are on track in the devise production. This will be revolutionary. If the final product does what DARPA wants it to be, this alone can open up the world market to AEMD and bring hug profits.
I am going to repeat something I have mentioned a few times before - esp. for Hep C, JJ should involve the Govt and insurance companies, show them that it is cost effective to use the HP and so consider it a standard of care along with other drugs. It may otherwise be hard to convince the medical field to embrace an invasive therapy (to be used with hemodialysis machines) to treat HepC, in spite of strong studies.
